In plants, activation of growth and activation of immunity are opposing processes that define a trade-off. In the past few years, the growth-promoting hormones brassinosteroids (BR) have emerged as negative regulators of pathogen-associated molecular pattern (PAMP)-triggered immunity (PTI), promoting growth at the expense of defense. The crosstalk between BR and PTI signaling was described as negative and unidirectional, since activation of PTI does not affect several analyzed steps in the BR signaling pathway. In this work, we describe that activation of PTI by the bacterial PAMP flg22 results in the reduced expression of BR biosynthetic genes. This effect does not require BR perception or signaling, and occurs within 15 min of flg22 treatment. Since the described PTI-induced repression of gene expression may result in a reduction in BR biosynthesis, the crosstalk between PTI and BR could actually be negative and bidirectional, a possibility that should be taken into account when considering the interaction between these two pathways.
INTRODUCTION
Plants need to integrate multiple environmental signals to finely regulate their growth and development in an adaptive manner. Activation of growth and activation of defense against potential pathogens are opposing processes, and the onset of one frequently results in inhibition of the other (Belkhadir et al., 2014; Huot et al., 2014) . In the absence of pathogen challenge, growth is prioritized over defense; upon detection of a pathogen, defense responses are initiated, at the expense of growth. This trade-off between growth and defense is regulated at multiple levels, and its control has been shown to depend on the action of several plant hormones, including jasmonates, gibberellins, brassinosteroids (BR), and salicylic acid (Navarro et al., 2008; Albrecht et al., 2012; Belkhadir et al., 2012; Yang et al., 2012; Lozano-Durán et al., 2013; Chandran et al., 2014; Fan et al., 2014; Malinovsky et al., 2014) .
The first layer of plant defense relies on the perception of conserved pathogen-associated molecular patterns (PAMPs) by pattern-recognition receptors (PRR) at the cell surface (Boller and Felix, 2009; Macho and Zipfel, 2014) . Recognition of a PAMP by the cognate PRR initiates a signaling cascade that involves signal transduction from the plasma membrane to the nucleus, where transcription is heavily reprogrammed. PAMP-triggered signaling ultimately leads to the activation of the so-called PAMP-triggered immunity (PTI), which is sufficient to ward off most potential pathogens. Activation of PTI also results in a strong inhibition of growth, which can be easily detected when seedlings are treated with certain PAMPs (Gomez-Gomez and Boller, 2000; Kunze et al., 2004) . Conversely, the growth-promoting hormones BR can inhibit PTI: activation (Albrecht et al., 2012; Belkhadir et al., 2012; LozanoDurán et al., 2013; Fan et al., 2014; Malinovsky et al., 2014) . Since activation of PTI was not found to affect the BR signaling pathway, the BR-PTI crosstalk was described as unidirectional and negative (Albrecht et al., 2012; Belkhadir et al., 2012) . In this work, we describe that activation of PTI by application of the bacterial PAMP flg22 results in the reduced expression of BR biosynthetic genes. This effect can be detected 15 min after treatment, and is sustained during a 24-h treatment. Moreover, this reduction of transcript levels does not require BR perception or signaling. Because the observed PTI-induced repression of gene expression may result in a decrease in BR biosynthesis, the crosstalk between PTI and BR could actually be indirect, negative, and bidirectional, a possibility that should be contemplated when considering the interaction between these two pathways.
RESULTS

Flg22 Treatment Results in the Repression of BR Biosynthetic Genes
Activation of PTI induced by treatment with the bacterial PAMP flg22 leads to heavy transcriptional reprogramming in plants Zipfel et al., 2004) . As part of these transcriptional changes, we observed that flg22 treatment consistently results in down-regulation of the BR marker gene CPD, which encodes a protein involved in BR biosynthesis (Szekeres et al., 1996 ; Table 1 ). An interrogation of publicly available microarray data (AtGenExpress collection; Schmid et al., 2005) revealed that flg22 treatment triggers a repression of several BR biosynthetic genes other than CPD, namely DWF4, BR6ox1, BR6ox2, CYP90C1, BAS1, SMT2, DWF1, and DWF7 ( Table 1) . Down-regulation of a subset of these genes can also be detected upon treatment with other PAMPs (Tables 1 and  2 ), although to a lesser extent. For further analyses, CPD and BR6ox2, which are repressed in response to both flg22 and elf18 (Zipfel et al., 2006 (Tables 1 and 2), were selected as marker genes, and their repression following flg22 treatment could be confirmed by qPCR ( Figure 1A) . A time-course analysis, depicted in Figure 1B , revealed that down-regulation of CPD and DWF4 upon flg22 treatment can be detected 15 min after treatment, and is maintained over a 24-h treatment.
The flg22-mediated Repression of BR Biosynthetic Genes is Independent of BR Perception
Because expression of BR biosynthetic genes is subjected to a negative feedback loop, and therefore these genes are repressed upon activation of BR signaling (Bancos et al., 2002; He et al., 2005; Tanaka et al., 2005; Sun et al., 2010; Yu et al., 2011) , we wondered whether the observed flg22-triggered repression of CPD and BR6ox2 required BR signaling. In order to determine this, we probed the expression changes of these two genes in the BR signaling mutants bri1-301, impaired in BR perception, and bin2-1, in which BR signaling is disrupted downstream of BR perception and upstream of BR-induced transcriptional changes (Peng et al., 2008; Xu et al., 2008) . In both mutants, repression of CPD and BR6ox2 could be detected after 1-or 24-h flg22 treatments (Figures 2A,B) , indicating that these expression changes do not require an intact BR signaling pathway. Brassinosteroids signaling, as PTI signaling, leads to the transcriptional reprogramming of the cell (Nemhauser et al., 2006; Sun et al., 2010; Yu et al., 2011) . The two major transcription factors mediating these changes are BZR1 and BES1 Yin et al., 2002; Sun et al., 2010; Yu et al., 2011) . Recently, BZR1 was described to mediate crosstalk between the BR and the PTI signaling pathways (Lozano-Durán et al., 2013); BES1 has also been proposed to interact with PTI responses (Kang et al., 2015) . Both CPD and BR6ox2 are targets of BZR1, which down-regulates their expression when activated (He et al., 2005; Sun et al., 2010) ; while CPD has also been found to be repressed by BES1, BR6ox2 has not (Yu et al., 2011) . The activation of BZR1 depends on its phospho-status, since only de-phosphorylated BZR1 is active Zhao et al., 2002; Gampala et al., 2007; Ryu et al., 2007) , as well as on the availability of interacting partners that act as transcriptional co-regulators (Luo et al., 2010; Bai et al., 2012; Gallego-Bartolome et al., 2012; Li et al., 2012; Oh et al., 2012) . Upon activation of BR signaling following BR perception, BZR1 is rapidly de-phosphorylated Tang et al., 2011) . In order to determine if the flg22-triggered down-regulation of CPD and BR6ox2 expression depends on BZR1, we investigated the phospho-status of this transcription factor (BZR1-YFP; Gampala et al., 2007) , as a proxy for its activation status, in response to flg22. As shown in Figure 3 , de-phosphorylated BZR1 can be detected following treatment with the BR brassinolide (BL), but not flg22; co-treatment with flg22 does not affect the effect of BL. Taken together, these results indicate that the flg22-triggered repression of CPD and BR6ox2 is independent of BR signaling.
DISCUSSION
A crosstalk between flg22-triggered and BR signaling had long been postulated, given that both signaling pathways (i) lead to opposing outcomes (i.e., onset of defense versus activation of growth), and (ii) share components involved in signal initiation or transduction (Belkhadir et al., 2014; Lozano-Durán and Zipfel, 2015) . Such an interaction was later experimentally confirmed and described to be negative, unidirectional (since only activation of BR signaling negatively affects PTI signaling, and not viceversa), and at least partially indirect (Vert and Chory, 2011; Albrecht et al., 2012; Belkhadir et al., 2012; Lozano-Durán et al., 2013; Fan et al., 2014; Malinovsky et al., 2014) . In these studies, however, activation of PTI signaling was achieved by exogenous flg22 treatment, within a time scale of min to very few hours, and therefore any potential longer-term effect of this pathway could have gone unnoticed. Additionally, activation of PTI could affect BR accumulation rather than sensitivity of the signaling pathway, which would be masked by exogenous hormone treatments or overexpression of rate-limiting components (Albrecht et al., 2012; Belkhadir et al., 2012) . Our results indicate that, although activation of PTI signaling by flg22 has been shown not to affect BR signaling (Albrecht et al., 2012; Belkhadir et al., 2012) , it leads to a repression of BR biosynthetic genes. This effect can be detected already 15 min after flg22 treatment, and is sustained during a 24-h treatment. The flg22-triggered transcriptional repression of the BR biosynthetic marker genes CPD and BR6ox2 does not require BR perception or signaling, and therefore we hypothesize that it is a direct effect of the activation of flg22-induced PTI signaling. Since the promoters of CPD and BR6ox2 contain binding sites for WRKY and MYB transcription factors (Figure 4 ; Athena; O'Connor et al., 2005) , which are known to mediate defense responses, one hypothesis would be that PTI-activated transcription factors, such as the ones belonging to these families, may directly mediate repression of BR biosynthetic genes. This potential PTI-mediated repression of BR biosynthesis could serve a double purpose: on one hand, it would work to alleviate the BR-mediated repression of PTI upon detection of an impending pathogen; on the other, it would inhibit BR-mediated growth, hence contributing to redirect resources towards immunity and away from growth.
MATERIALS AND METHODS
Plant Materials and Growth Conditions
Arabidopsis thaliana Col-0 was used as genetic background for all experiments. Seedlings were grown as described in LozanoDurán et al., 2013 . The mutant lines bri1-301 and bin2-1 and the transgenic line BZR1-YFP have been previously characterized (Gampala et al., 2007; Peng et al., 2008; Xu et al., 2008) .
RNA Extraction
RNA was extracted from 14-day-old seedlings as described in (Couto et al., 2015) .
Quantitative Real-time PCR
First-strand cDNA synthesis was performed with the SuperScript III RNA transcriptase (Invitrogen) and oligo(dT) primer, according to the manufacturer's instructions. For qPCR reactions, the reaction mixture consisted of cDNA first-strand template, primers (10 pmol each) and SYBR Green JumpStart Taq ReadyMix (Sigma). qPCR was performed in a BioRad CFX96 real-time system. UBQ10 was used as the internal control; expression in mock-treated Col-0 seedlings was used as the calibrator, with the expression level set to one. Relative expression was determined using the comparative Ct method (2-∆∆Ct). Each data point is the mean value of three biological replicates.
Protein Extraction and Immunoblotting
Protein extraction from 14-day-old seedlings and immunoblotting were performed as described in (Albrecht et al., 2012) .
